[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636092":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":29,"responsibleParty":83,"collaborators":10,"id":85,"slug":86,"hasResults":87,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":87,"sex":93,"minAge":94,"maxAge":10,"enrollmentInfo":95,"targetDuration":10,"studyType":98,"phases":10,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":116},{"fullName":5,"class":6},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"C1 - Training set",null,"A prospective cohort of MPM patients enrolled. Analyses will be performed on fresh frozen (FF) tumor samples derived from diagnostic biopsies, surgical resections, or malignant pleural effusions (MPE).",{"label":13,"type":10,"description":14,"interventionNames":10},"C2 - Validation Set","An independent retrospective cohort of MPM samples collected between 2015 and 2022. This cohort will serve to validate findings obtained in the training set.",{"label":16,"type":10,"description":17,"interventionNames":10},"C3 - HITHOC Set","An prospective cohort of patients undergoing surgery combined with hyperthermic intrathoracic chemotherapy (HITHOC). This cohort will enable investigation of tumor-immune interactions and treatment response mechanisms in this specific clinical setting.",[19],{"name":20,"affiliation":21,"role":22},"Alessia Ciarrocchi","Azienda USL - IRCCS di Reggio Emilia","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Alessia Ciarrocchi, PhD","CONTACT","0522\u002F295668","alessia.ciarrocchi@ausl.re.it",[30,47,59,70],{"facility":31,"status":32,"city":33,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Azienda Ospedaliera Universitaria Policlinico Rodolico San Marco di Catania","RECRUITING","Catania","Italy","IT",{"type":37,"coordinates":38},"Point",[39,40],15.07041,37.49223,{"lat":40,"lon":39},[43],{"name":44,"role":26,"phone":45,"phoneExt":10,"email":46},"Giacomo Cusumano, MD PhD","095 3781175","giacomo.cusumano@unict.it",{"facility":48,"status":32,"city":49,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":50,"geoPoint":54,"contacts":55},"Azienda Ospedaliera Universitaria Luigi Vanvitelli, Napoli","Naples",{"type":37,"coordinates":51},[52,53],14.26811,40.85216,{"lat":53,"lon":52},[56],{"name":57,"role":26,"phone":10,"phoneExt":10,"email":58},"Alfonso Fiorelli, MD PhD","alfonso.fiorelli@unicampania.it",{"facility":60,"status":32,"city":61,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Azienda USL IRCCS di Reggio Emilia","Reggio Emilia",{"type":37,"coordinates":63},[64,65],10.63125,44.69825,{"lat":65,"lon":64},[68,69],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":25,"role":22,"phone":10,"phoneExt":10,"email":10},{"facility":71,"status":32,"city":72,"state":10,"zip":10,"country":34,"countryCode":35,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","Roma",{"type":37,"coordinates":74},[75,76],11.10642,44.99364,{"lat":76,"lon":75},[79],{"name":80,"role":26,"phone":81,"phoneExt":10,"email":82},"Filippo Lococo, MD","06 8881 8881","filippo.lococo@policlinicogemelli.it",{"type":84,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100636092","multidimensional-omics-analysis-in-malignant-pleural-mesothelioma-100636092",false,"NCT07561190","Multidimensional Omics Analysis in Malignant Pleural Mesothelioma","Multidimensional Omics and Functional Approaches to Improve Immunotherapy Efficacy in Malignant Pleural Mesothelioma","OMIM","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study\n* Aged \\> 18 years\n* Patients with histologically confirmed diagnosis of MPM\n* Availability of biological material\n* Clinical indicatio of eligibility for HITOCH protocol (only for C3 cohort)\n\nExclusion Criteria:\n\n* Active current infection\n* Autoimmune disease\n* Women in childbearing age not able to exclude pregnancy","ALL","18 Years",{"count":96,"type":97},300,"ESTIMATED","OBSERVATIONAL","Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited. The lack of prognostic biomarkers further complicates the decision-making. Recently, the introduction of immune checkpoint inhibitors (ICIs) has marked a shift but has failed to produce significant benefits for a large proportion of patients. Maximizing the efficiency of ICIs and developing new protocols to improve drug efficacy is the best possible strategy for improving the life expectancy and quality of life of patients with MPM. This study aims to characterize the organization of the immune system infiltrating mesothelioma and the dynamics of its interaction with the tumor. The rationale is that deciphering this complexity will help improve our understanding of the mechanisms underlying this disease and provide a new tool to optimize the use of ICIs in these patients.",[101],"Malignant Pleural Mesothelioma (MPM)",[103,104,105,106],"chronic inflammation","biomarkers","immune-related markers","asbestos exposure","2026-04-24",{"date":109,"type":110},"2026-05-01","ACTUAL",{"date":112,"type":110},"2024-08-30",{"date":114,"type":97},"2027-02-28",{"name":5,"class":6},4]